Seeking Alpha

Inovio responds to Mr. Feuerstein's article

  • Inovio Pharmaceuticals (INO +1.6%) takes umbrage over yesterday's bearish article published by TheStreet's Adam Feuerstein. In today's press release, the company says it intends to report VGX-3100's Phase 2 data at the end of July. At present, it remains blinded.
  • Pertaining to efficacy, the study measures regression of disease from late-stage cervical pre-cancer (CIN 2/3) to early stage pre-cancer (CIN 1) or elimination of disease. The study is 80% powered to achieve a 52% response rate in vaccinated subjects compared to a hypothetical 25% in the control group. The 25% figure is based on natural regression response rates that have ranged from 4% - 40% in other studies.
  • CEO Joseph Kim will undoubtedly join Northwest Biotherapeutics (NWBO +5.8%) Chief Linda Powers in declining a dinner invitation with Mr. Feuerstein.
From other sites
Comments (19)
  • lbashaw
    , contributor
    Comments (28) | Send Message
     
    the baffle them with bs defense release didnt work....pros are dumping all over mom and pop retail buyers
    11 Jun 2014, 10:19 AM Reply Like
  • evilbarbie
    , contributor
    Comments (64) | Send Message
     
    It is all clear now....this is how Adam tries to get dates.
    11 Jun 2014, 10:23 AM Reply Like
  • Erbois
    , contributor
    Comments (224) | Send Message
     
    Who would want to dine with a face like that? :-(

     

    I think this guy is trying to hold these companies to ransom. As his "publication" is almost bankrupt, he is trying another way to make money.
    11 Jun 2014, 10:35 AM Reply Like
  • pat walsh
    , contributor
    Comments (306) | Send Message
     
    AF needs to see a doctor.he has mental problems.
    11 Jun 2014, 11:00 AM Reply Like
  • asclepius8
    , contributor
    Comments (943) | Send Message
     
    AF is so driven to validate his "Feuerstein-Ratain Rule", everything else be damned. While its an interesting statistic, I suspect the tail is wagging the dog in some of these cases.
    11 Jun 2014, 11:14 AM Reply Like
  • dme306
    , contributor
    Comments (56) | Send Message
     
    Honestly, his shot at successfully using this "self-contrived" Rule is nearly a can't miss, right. More than 80% of these trials fail...I'll take 80% in Vegas too.
    11 Jun 2014, 09:40 PM Reply Like
  • emuziek
    , contributor
    Comments (30) | Send Message
     
    Opprobrius effluvium. I always enjoy reading articles from both sides - albeit mostly for the entertainment value. - Do your own due diligence.
    11 Jun 2014, 11:43 AM Reply Like
  • moves
    , contributor
    Comments (23) | Send Message
     
    "I tried a two-year spin on Wall Street as a buyside Analyst and well, let's just say I am a better writer..." -Adam Feuerstein
    11 Jun 2014, 12:05 PM Reply Like
  • mark woods
    , contributor
    Comments (191) | Send Message
     
    INO

     

    Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.

     

    Detractors.....adam Feuerstein
    11 Jun 2014, 12:25 PM Reply Like
  • egnorops
    , contributor
    Comments (31) | Send Message
     
    This is a lame , half hearted rebuttal . It would have been more effective to simply cut and paste Inovio's PR. There is no outrage as these hedge fund hit men like AF butcher the facts. The SEC is weak and even appears corrupt as they turn a blind eye to this blatant manipulation.
    11 Jun 2014, 12:41 PM Reply Like
  • wmcraigbarnard
    , contributor
    Comments (206) | Send Message
     
    As I have stated in another article Mr. F is not educated in the material he reports on. No offense to Mr. AF. It's just a fact born out in this situation. In other words he has no science background and simply sells what he thinks. It isn't "priceless" it's useless.

     

    If "The Street" wishes to follow Bio Medical companies it would be nice if they would at least find a science major with a minor in Business to investigate these companies. That person should understand the language and have the training to ascertain the facts clinically. If not find an experienced retired FDA guy.
    11 Jun 2014, 04:40 PM Reply Like
  • asclepius8
    , contributor
    Comments (943) | Send Message
     
    AF is the "chicken little" of the biotech world. Just once I'd like to hear him rave about a company, but no. Never.
    11 Jun 2014, 04:53 PM Reply Like
  • wmcraigbarnard
    , contributor
    Comments (206) | Send Message
     
    What you describe it his industry persona.

     

    Unfortunate, if one doesn't know what they are talking about you go with percentages. Example: 1. Cancer approvals are 20F's/1S failures and 2. the average market see's approximately 10F's/1S failure rates.

     

    I suspect AF plays the averages rather then follow the facts and dig for the truth. It takes real work few are willing to do and have the correct experience to make for a respectable commentator. One must have a science background, awareness of FDA procedures, business acumen and inside contacts. I'm not seeing this in Mr. AF background.

     

    No insult intended. I'm just describing what I see.
    12 Jun 2014, 04:39 PM Reply Like
  • WHO73
    , contributor
    Comments (3) | Send Message
     
    AF wrote a similar opinion on NWBO , 27-29 May. Since then NWBO stock has increased by 103 percent YTD. For all you investors wishing to invest on emotion instead of reason (DD) just keep listening to A F.
    14 Jun 2014, 12:36 AM Reply Like
  • rx7no1
    , contributor
    Comments (7) | Send Message
     
    If AF had done a similar hatched job on GE that caused a similar perecentage of loss to its shareholders there would be a congressional hearing on what went down.
    AF knows he can get away with it with small biotecs like INO since the SEC really won't bother when a small fish is flushed down a toilet by characters like him.
    Adam is just the jerk who keys your car because he resents that you have a pretty girlfriend and he only has internet porn.
    11 Jun 2014, 11:09 PM Reply Like
  • Montyinfl
    , contributor
    Comments (18) | Send Message
     
    Too many speculators manupulating the stock with no fundamentals to back up except for making a short term profit. Once the stock hits 12 -15 range shorts will run for cover.
    11 Jun 2014, 11:09 PM Reply Like
  • Clinically Sound Investor
    , contributor
    Comments (306) | Send Message
     
    Dude, INO already hit $12.20 when the Fraudstein piece came out. Bet you the Street made a pretty penny shorting.
    12 Jun 2014, 01:15 AM Reply Like
  • emuziek
    , contributor
    Comments (30) | Send Message
     
    At what point does this escallate from groundless unfounded criticism to potential legal action?
    12 Jun 2014, 08:06 AM Reply Like
  • wmcraigbarnard
    , contributor
    Comments (206) | Send Message
     
    SEC.Gov. Go for it.
    12 Jun 2014, 04:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs